Phase 2 N=290 Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study
Pain
Primary: Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6) — 2.36; 25.59; 30.28; 33.77 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived
Glaucoma
Primary: Overall Responder Rate — 3 Participants
N/A N=127 The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
Type1 Diabetes Mellitus
Primary: Time Below 70 mg/dL — 2.4; 4.0 percentage of total CGM time — p=<0.0001
Phase 2 N=31 The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
Primary: Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients — 656.8; 190.9; 681.3; 156.9 ng/mL
N/A N=30 Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery
Type 1 Diabetes Mellitus
Primary: Number of SAE or ADE Related to the Use of ATM / WST and BAM Modules. — 0; 0 events
Phase 2 N=56 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Head and Neck Squamous Cell Carcinoma · Breast Cancer · Sarcoma
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 4; 5; 1; 15 Participants
Phase 2 N=33 Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Loss of Chromosome 17p · Recurrent Plasma Cell Myeloma
Primary: The Number of Participants Who Experienced Dose Limiting Toxicities. Maximum Tolerated Dose (MTD) of Ixazomib Citrate and Idasanutlin in Combination With Dexamethasone…
N/A N=40 Performance of QDOT Micro™ Catheter With nGEN Generator for Patients With AFIB.
Atrial Fibrillation
Primary: Number of Participants Who Achieved Acute Procedural Success — 37 Participants
Phase 3 N=262 Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
Advanced Parkinson's Disease
Primary: Number of Participants With Treatment-emergent Adverse Events — 253; 219; 159; 152 Participants
N/A N=4,852 Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa
Tuberculosis
Primary: Treatment Initiation Ratio in Facility Versus Contact Investigation Clinics — 1929; 1726 Participants — p=0.73
N/A N=37 Peer-Delivered Behavioral Activation for Methadone Adherence - Pilot Phase
Substance Use · Substance Use Disorders · Opioid-use Disorder
Primary: MOUD Retention Rate: % of Patients Retained at 3 Months — 31 Participants
Phase 2 N=60 Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects
Dry Eye Disease
Primary: Total Ocular Surface Disease Index — 21.17; 21.36 score on a scale — p=0.967
N/A N=35 The International Diabetes Closed Loop (iDCL) Trial: Protocol 4
Type 1 Diabetes
Primary: Percent CGM Time in Range 70-180 mg/dL — 69; 66 percentage of time
N/A N=72 Tailoring Treatment Targets for Early Autism Intervention in Africa
Autism Spectrum Disorder
Primary: Supported Joint Engagement Measured by the Joint Engagement Rating Inventory (JERI) — 6; 4; 2; 4 score on a scale — p=1.00
Phase 4 N=30 Tocilizumab Plus a Short Prednisone Taper for GCA
Giant Cell Arteritis
Primary: Sustained Remission — 23 Participants